A one-year, multicenter, randomized, double-blind, placebo-controlled, parallel group study to determine the efficacy and safety of 35-mg risedronate administered once a week in the prevention of osteoporosis in postmenopausal women.

Trial Profile

A one-year, multicenter, randomized, double-blind, placebo-controlled, parallel group study to determine the efficacy and safety of 35-mg risedronate administered once a week in the prevention of osteoporosis in postmenopausal women.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Aventis
  • Most Recent Events

    • 14 Apr 2009 Actual end date (Jun 2004) added as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Actual patient number (260) added as reported by ClinicalTrials.gov.
    • 02 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top